不过,在三星 Bioepis 2025 年第一季度的《生物仿制药市场动态》报告中,Humira 仍占据阿达木单抗 72% 的市场份额,在 2024 年第三季度版本中,其市场份额为 82%,显示出一定的市场韧性。 九、人乳头瘤病毒疫苗(Gardasil) 作为榜单上唯一的疫苗,默沙东的人乳头瘤病毒疫苗 Gardasil 在 2024 年销售额下降 3%,为 85.8...
为应对可能的收入损失,百时美施贵宝启动数十亿美元节约计划,目标到 2025 年底削减 15 亿美元成本,2027 年再削减 20 亿美元;辉瑞也设定了 2024 年 35 亿美元的节约目标,到 2027 年底再削减 15 亿美元。 五、度普利尤单抗(Dupixent) 赛诺菲和再生元联合商业化的免疫学重磅药物 Dupixent,2024 年销售额达 130.72 ...
December 31, 2024 Top drugs viewed by neurologists in 2024 in epocrates: Nurtec ODT (rimegepant) Xcopri (cenobamate) Qulipta (atogepant) Ozempic (semaglutide) Ubrelvy (ubrogepant) Rexulti (brexpiprazole) Mounjaro (tirzepatide) Kesimpta (ofatumumab) Briviact (brivaracetam) Vyvgart (efgar...
Over the last years, Keytruda was ranked first among the top cancer drugs worldwide based on revenue. The oncology market was for years dominated by Roche’s top products, Rituxan, Herceptin, and Avastin, as well as Celgene’s (BMS's) Revlimid. As of today, Keytruda is the global top ...
Top drugs viewed by cardiologists in 2024 in epocrates: Ozempic (semaglutide) Jardiance (empagliflozin) Farxiga (dapagliflozin) Mounjaro (tirzepatide) Wegovy (semaglutide) Repatha (evolocumab) Zepbound (tirzepatide) amoxicillin metformin cephalexinTRENDING THIS WEEK EPOCRATES CME View Catalog Clinical...
Novartis' top drugs based on revenue 2024 Published by , Feb 4, 2025 Cardiovascular drug Entresto was Novartis’ best-selling pharmaceutical during 2024, with a total revenue of around 7.8 billion U.S. dollars worldwide. Novartis is one of the big pharma companies with the lowest share of...
NO. 1 KeytrudaCompany: Merck & Co.2024 worldwide sales forecast: $27.19 billion In September 2014, the U.S. Food and Drug Administration (FDA) approved Keytruda (Pembrolizumab), a PD-1 monoclonal antibody for the treatment of cancer. For the first four years since approval, the Keytruda un...
You do not necessarily have to reach to a specialist right away or get your little one stuffed with drugs. Instead, there are natural ways to reduce your little one's hyperactivity in a simple and efficient manner. This book will help you understand the severity of your kid's hyperactivity...
over-the-counter drugs, wound care and women’s health, with leading brands like Band-Aid, Benadryl, Neutrogena and Clean & Clear on its portfolio. The Pharmaceuticals segment offers medicines under the verticals of immunology, infectious diseases and vaccines, neuroscience, oncology, cardiovascular ...
Also on the vaccine front, Takeda plans to file soon for approval of its dengue fever shot, TAK-003. It’s among a dozen new drugs Takeda aims to launch by fiscal year 2024 that it said could bring in combined peak sales of more than $10 billion. ...